Correlation Engine 2.0
Clear Search sequence regions


  • Arid1a (1)
  • Arid2 (1)
  • cancers (3)
  • cellular (1)
  • chromatin (5)
  • impairment (1)
  • in p (1)
  • MAPK (4)
  • mice (2)
  • silences genes (1)
  • Smarcb1 (1)
  • SNF (4)
  • strains (1)
  • subunits (5)
  • SWI (4)
  • swi snf complex (2)
  • therapies (2)
  • thyroid (4)
  • thyroid cancers (4)
  • thyroid tumor (2)
  • tumors promotes (1)
  • Sizes of these terms reflect their relevance to your search.

    Mutations of subunits of the SWI/SNF chromatin remodeling complexes occur commonly in cancers of different lineages, including advanced thyroid cancers. Here we show that thyroid-specific loss of Arid1a, Arid2, or Smarcb1 in mouse BRAFV600E-mutant tumors promotes disease progression and decreased survival, associated with lesion-specific effects on chromatin accessibility and differentiation. As compared with normal thyrocytes, BRAFV600E-mutant mouse papillary thyroid cancers have decreased lineage transcription factor expression and accessibility to their target DNA binding sites, leading to impairment of thyroid-differentiated gene expression and radioiodine incorporation, which is rescued by MAPK inhibition. Loss of individual SWI/SNF subunits in BRAF tumors leads to a repressive chromatin state that cannot be reversed by MAPK pathway blockade, rendering them insensitive to its redifferentiation effects. Our results show that SWI/SNF complexes are central to the maintenance of differentiated function in thyroid cancers, and their loss confers radioiodine refractoriness and resistance to MAPK inhibitor-based redifferentiation therapies. SIGNIFICANCE: Reprogramming cancer differentiation confers therapeutic benefit in various disease contexts. Oncogenic BRAF silences genes required for radioiodine responsiveness in thyroid cancer. Mutations in SWI/SNF genes result in loss of chromatin accessibility at thyroid lineage specification genes in BRAF-mutant thyroid tumors, rendering them insensitive to the redifferentiation effects of MAPK blockade.This article is highlighted in the In This Issue feature, p. 995. ©2020 American Association for Cancer Research.

    Citation

    Mahesh Saqcena, Luis Javier Leandro-Garcia, Jesper L V Maag, Vatche Tchekmedyian, Gnana P Krishnamoorthy, Prasanna P Tamarapu, Vera Tiedje, Vincent Reuter, Jeffrey A Knauf, Elisa de Stanchina, Bin Xu, Xiao-Hui Liao, Samuel Refetoff, Ronald Ghossein, Ping Chi, Alan L Ho, Richard P Koche, James A Fagin. SWI/SNF Complex Mutations Promote Thyroid Tumor Progression and Insensitivity to Redifferentiation Therapies. Cancer discovery. 2021 May;11(5):1158-1175

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 33318036

    View Full Text